Status:
UNKNOWN
Phase I/II Study of Recombinant Human Hepatocyte Growth Factor in Fulminant Hepatic Failure
Lead Sponsor:
Kyoto University, Graduate School of Medicine
Conditions:
Liver Failure, Acute
Eligibility:
All Genders
16+ years
Phase:
PHASE1
PHASE2
Brief Summary
The purpose of this study is to determine whether recombinant human hepatocyte growth factor is safe and effective in the treatment of fulminant and late-onset hepatic failure.
Detailed Description
Fulminant and late-onset hepatic failure (LOHF) is intractable disease with high degree of fatality (70-80%). Only liver transplantation is established as a therapeutic modality to rescue patients wit...
Eligibility Criteria
Inclusion
- Clinical diagnosis of fulminant or late-onset hepatic failure
- Must be unable to receive liver transplantation
Exclusion
- Under 16 years old
- Cancer patients
- Pregnancy-aged women
- Impaired renal function
- Impaired cardiac function
- Severe complications including pneumonia, sepsis, DIC and so on
Key Trial Info
Start Date :
September 1 2005
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT00225901
Start Date
September 1 2005
Last Update
September 26 2005
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kyoto University Hospital
Kyoto, Kyoto, Japan, 606-8507